Abstract
Alzheimers and Parkinsons diseases represent the most prevalent neurodegenerative disorders worldwide. Current pharmacological or surgical treatments provide symptomatic benefits, particularly in the early stages, but none can delay or stop the progression of these diseases. There is an urgent need for new therapies able to modify disease progression. Gene therapy, mainly based on viral vectors, is presently being assumed as an important alternative to conventional treatments. After decades of preclinical developments, we are now facing an important period, in which several viral vector – mediated gene therapies are being tested in Phase 1 and Phase 2 clinical trials, with some of them showing promising results. This review intends to present an overview of the current efforts in the field for the treatment of Alzheimers and Parkinsons diseases.
Keywords: Parkinson's disease, Alzheimer's disease, neurodegenerative, gene transfer, molecular therapy, viral vectors, AAV, lentivirus, neurotrophic factors, genetic immunization
Current Pharmaceutical Design
Title: Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials
Volume: 17 Issue: 31
Author(s): Rui Jorge Nobre and Luis Pereira de Almeida
Affiliation:
Keywords: Parkinson's disease, Alzheimer's disease, neurodegenerative, gene transfer, molecular therapy, viral vectors, AAV, lentivirus, neurotrophic factors, genetic immunization
Abstract: Alzheimers and Parkinsons diseases represent the most prevalent neurodegenerative disorders worldwide. Current pharmacological or surgical treatments provide symptomatic benefits, particularly in the early stages, but none can delay or stop the progression of these diseases. There is an urgent need for new therapies able to modify disease progression. Gene therapy, mainly based on viral vectors, is presently being assumed as an important alternative to conventional treatments. After decades of preclinical developments, we are now facing an important period, in which several viral vector – mediated gene therapies are being tested in Phase 1 and Phase 2 clinical trials, with some of them showing promising results. This review intends to present an overview of the current efforts in the field for the treatment of Alzheimers and Parkinsons diseases.
Export Options
About this article
Cite this article as:
Jorge Nobre Rui and Pereira de Almeida Luis, Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials, Current Pharmaceutical Design 2011; 17 (31) . https://dx.doi.org/10.2174/138161211798072472
DOI https://dx.doi.org/10.2174/138161211798072472 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multidisciplinary Cancer Therapy with Telomerase-Specific Oncolytic Adenovirus
Current Cancer Therapy Reviews In Vivo Anticancer Activity, Toxicology and Histopathological Studies of the Thiolate Gold(I) Complex [Au(Spyrimidine)(PTA-CH<sub>2</sub>Ph)]Br
Anti-Cancer Agents in Medicinal Chemistry Targeting SphK1 as a New Strategy against Cancer
Current Drug Targets KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma
Current Neuropharmacology Patents Review in siRNA Delivery for Pulmonary Disorders
Recent Patents on Drug Delivery & Formulation Dysregulated Pathway Identification of Alzheimer's Disease Based on Internal Correlation Analysis of Genes and Pathways
Combinatorial Chemistry & High Throughput Screening Notch-Associated MicroRNAs in Cancer
Current Drug Targets Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry Lipid-Based Drug Delivery Systems for Cancer Treatment
Current Drug Targets The Role of the Endoplasmic Reticulum in the Accumulation of β-Amyloid Peptide in Alzheimers Disease
Current Molecular Medicine Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective
Current Pharmaceutical Design Presenilin and γ -Secretase Activity: A Viable Therapeutic Target for Alzheimers Disease?
Current Signal Transduction Therapy Crocetin, a Carotenoid Derivative, Inhibits VEGF-Induced Angiogenesis via Suppression of p38 Phosphorylation
Current Neurovascular Research Inhibitory Smad7: Emerging Roles in Health and Disease
Current Molecular Pharmacology Histone Deacetylase (HDAC) Inhibitors as Potential Drugs to Target Memory and Adult Hippocampal Neurogenesis
Current Psychopharmacology C-11 Radiochemistry in Cancer Imaging Applications
Current Topics in Medicinal Chemistry Targeting Apoptosis Pathways in Cancer Therapy
Current Cancer Drug Targets Expression of Rab3b in Human Glioma: Influence on Cell Proliferation and Apoptosis
Current Pharmaceutical Design Lycorine and its Derivatives for Anticancer Drug Design
Mini-Reviews in Medicinal Chemistry Therapeutic Potential of Perineural Invasion, Hypoxia and Desmoplasia in Pancreatic Cancer
Current Pharmaceutical Design